Stockscreener 앱 받기
1.42
1.39%
-0.02
시간 외 거래:
1.42
전일 마감가:
$1.44
열려 있는:
$1.41
하루 거래량:
1.97M
Relative Volume:
0.62
시가총액:
$380.39M
수익:
$236.20M
순이익/손실:
$-5.35M
주가수익비율:
-79.33
EPS:
-0.0179
순현금흐름:
$67.70M
1주 성능:
+1.43%
1개월 성능:
+20.34%
6개월 성능:
-49.65%
1년 성능:
-50.00%
1일 변동 폭
$1.39
$1.44
1주일 범위
$1.39
$1.56
52주 변동 폭
$1.14
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.42 | 385.75M | 236.20M | -5.35M | 67.70M | -0.0179 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - The Manila Times
Three kidney disease programs take center stage at Akebia's April 2 R&D Day - Stock Titan
Is the Options Market Signaling a Surge in Akebia Therapeutics Shares? - Bitget
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Akebia Q2 2025 Earnings Preview - MSN
AKBA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus
Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN
Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference - MarketBeat
Akebia Therapeutics Earnings Call: Vafseo Drives Growth - The Globe and Mail
Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline By Investing.com - Investing.com Canada
How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset - Yahoo Finance
Akebia tops Q4 revenue expectations as Vafseo momentum strengthens outlook - MSN
Piper Sandler lowers Akebia Therapeutics (AKBA) PT to $4 as firm updates estimates following year-end reports - MSN
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - MSN
Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares - MarketBeat
Layoff Watch: Does Akebia Therapeutics Inc offer margin of safety2025 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - The Globe and Mail
Akebia Therapeutics CEO to speak at Miami Leerink 2026 healthcare forum - Stock Titan
Akebia Therapeutics Reports Inducement Grants - National Today
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics (NASDAQ:AKBA) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A Potential 233% Upside in the Healthcare Sector - DirectorsTalk Interviews
Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Loss In Q4 2025 Tests Bullish Margin Narratives - simplywall.st
Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Akebia Therapeutics, Inc. posts full year 2025 financial results amid commercial and pipeline expansion - Traders Union
Key facts: Akebia Therapeutics reports 47% revenue rise; Phase 2 trials planned - TradingView
Akebia (AKBA) Q4 2025 Earnings Call Transcript - AOL.com
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Akebia Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
Akebia Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
AKBA: Vafseo launch drove 50% revenue growth in 2025, with expanding adoption and robust cash reserves - TradingView
Akebia Therapeutics Q4 Earnings Call Highlights - MarketBeat
Akebia Therapeutics Inc (NASDAQ:AKBA) Reports Q4 Revenue Beat and 49% Annual Growth Amid Mixed Market Reaction - ChartMill
Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo - GuruFocus
AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings - Quiver Quantitative
Akebia Therapeutics, Inc. Q4 Loss Decreases - Nasdaq
Akebia Therapeutics, Inc. SEC 10-K Report - TradingView
AKBA: Revenue surged 47% to $236.2M in 2025, with Vafseo launch and pipeline expansion offsetting Auryxia LoE - TradingView
Akebia Therapeutics: Q4 Earnings Snapshot - Barchart.com
[8-K] Akebia Therapeutics, Inc. Reports Material Event | AKBA SEC FilingForm 8-K - Stock Titan
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - The Manila Times
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):